DelveInsight's "Exocrine Pancreatic Insufficiency - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Exocrine Pancreatic Insufficiency, historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Exocrine Pancreatic Insufficiency market report provides current treatment practices, emerging drugs, Exocrine Pancreatic Insufficiency market share of the individual therapies, current and forecasted Exocrine Pancreatic Insufficiency market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Exocrine Pancreatic Insufficiency treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Exocrine pancreatic insufficiency (EPI) refers to the presence of maldigestion and malabsorption of such nutrients. It is a consequence of the primary loss of functional parenchyma and/or secondarily impaired exocrine pancreatic function and insufficient pancreatic enzyme activity. EPI is sometimes defined simply as an enzyme output less than 10% of that necessary to sustain normal digestion; however, there is no consensus in the literature on the definition of EPI.
Furthermore, the clinical presentation of EPI can vary widely depending on the underlying cause, as well as disease stage, diet, and other factors. EPI is most commonly caused by diseases that destroy the pancreatic parenchyma, such as chronic pancreatitis and cystic fibrosis, as well as pancreatic resection. The incidence of EPI in chronic pancreatitis ranges from 30% of patients with mild disease to 85% with severe disease. Approximately 85% of infants with cystic fibrosis have EPI at birth.
There are several causes of Exocrine Pancreatic Insufficiency (EPI) which include Diabetes, Pancreatic cancer, Celiac disease, HIV/AIDS, Chronic Pancreatitis, Cystic Fibrosis Ulcerative Colitis, Schwachman–Diamond Syndrome, and others.
Exocrine pancreatic insufficiency Diagnosis
The diagnostic approach to EPI can be addressed to evaluate the maldigestion of nutrients or to quantify the exocrine pancreatic secretion specifically. Two categories of tests can be distinguished: direct and indirect. Indirect tests assess the consequence of exocrine insufficiency, evaluating quantitative changes of pancreatic secretion. Direct tests evaluate the secretive production directly, and, despite their good sensitivity, are invasive, time-consuming, expensive, and not useful in monitoring the response to pancreatic enzyme replacement therapy (PERT).
Moreover, they are not standardized because of lack of consensus about protocol, and present extensive variation in results, and are not widely available. The indirect tests includes Stool tests Coefficient of fat absorption, Fecal elastase-1 (FE-1), Stool chymotrypsin, Blood test Serum immunoreactive trypsinogen (IRT), and others whereas the direct tests for EPI includes Endoscopic secretin or CCK based pancreatic stimulation test, and Secretin-enhanced magnetic resonance cholangiopancreatography (s-MRCP).
Exocrine pancreatic insufficiency Treatment
Patients with EPI may be treated with Pancreatic enzyme replacement therapy (PERT) to aid in the digestion and absorption of fats; PERT is recommended for patients with EPI to address weight loss, malnutrition, and steatorrhea. Briefly, treatment is primarily based on oral PERT regimens to correct malnutrition and improve symptoms. The current drugs that fall under PERT includes Creon, Zenpep, Pancreaze, Viokase, and Pertzye respectively, Underlying diseases leading to EPI should be treated, and lifestyle modifications should also be undertaken, including alcohol abstinence (to reduce pain and increase gastric lipase secretion) and supplementation of fat-soluble vitamins as needed.
Dietary fat restriction is not necessary, especially for patients on enzyme supplementation. Frequent, low-volume meals are recommended, and difficult-to-digest foods such as legumes should be avoided.
It covers the details of conventional and current medical therapies available in the Exocrine Pancreatic Insufficiency (EPI) market for the treatment of the various types of Exocrine Pancreatic Insufficiency (EPI). It also provides the treatment guidelines and algorithms of the United States and Europe. The DelveInsight’s Exocrine Pancreatic Insufficiency (EPI) market report gives a thorough understanding of Exocrine Pancreatic Insufficiency (EPI) by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Causative Indications of EPI and Prevalence of Exocrine Pancreatic Insufficiency scenario of Exocrine Pancreatic Insufficiency (EPI) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Key Findings
This section provides glimpse of the Exocrine Pancreatic Insufficiency (EPI) epidemiology in the 7MM.
The epidemiology segment also provides the Exocrine Pancreatic Insufficiency (EPI) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The drug chapter segment of the Exocrine Pancreatic Insufficiency (EPI) report encloses the detailed analysis of Exocrine Pancreatic Insufficiency (EPI) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Exocrine Pancreatic Insufficiency (EPI) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
Exocrine Pancreatic Insufficiency (EPI) Marketed Drugs
Pertzye (pancrelipase): Digestive Care
Pertzye (pancrelipase)—a combination of porcine-derived lipases, proteases, and amylases—developed by Digestive Care is an orally administered drug in patients with exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. The pancreatic enzymes in Pertzye catalyze the hydrolysis of fats to monoglyceride, glycerol, and free fatty acids; proteins into peptides and amino acids; and starches into dextrins and short-chain sugars—maltose and maltotriose—in the duodenum and proximal small intestine, thereby, acting like digestive enzymes secreted by the pancreas physiologically. Digestive Care and its marketing partner Chiesi, in July 2017, announced FDA approval of a 24,000 USP lipase units capsule of Pertzye (pancrelipase) delayed-release capsules to treat exocrine pancreatic insufficiency (EPI). The newly available dosing strength caters specifically to children over 12 months and adults, which may allow for consumption of fewer capsules to reach the needed weight-based dose when compared to the other Pertzye capsule sizes.
Products detail in the report…
Creon (pancrelipase)/Lipacreon: AbbVie
Creon capsule, initially developed by Solvay Pharmaceuticals, is a pancrelipase—a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of EPI due to cystic fibrosis or other conditions. In June 2011, Abbott announced that the FDA had approved an infant-specific dose of Creon (pancrelipase) delayed-release capsules to treat EPI due to cystic fibrosis (CF). In April 2011, Abbott and Eisai received approval to market the pancreatic enzyme replacement drug Lipacreon (pancrelipase) in Japan as a pancreatic digestive enzyme replacement in patients with pancreatic exocrine insufficiency.
Products detail in the report…
Zenpep (pancrelipase): Nestle
In August 2009, Eurand announced the commercial availability of Zenpep (pancrelipase) delayed-release capsules, a pancreatic enzyme product (PEP) indicated for the treatment of exocrine pancreatic EPI due to cystic fibrosis (CF) or other conditions. In January 2007, Zenpep received a fast track designation from the US FDA. In January 2020, Nestle announced that it has entered into an asset purchase agreement with Allergan to acquire Zenpep. This move aims to expand the company's medical nutrition business and complement its portfolio of therapeutic products.
Products detail in the report…
Exocrine Pancreatic Insufficiency (EPI) Emerging Drugs
MS1819-SD: AzurRx BioPharma
AzurRx BioPharma specializes in the development of non-systemic, recombinant therapies for gastrointestinal diseases. The company is developing MS1819-SD, a yeast-derived recombinant lipase—an enzyme that breaks up fat molecules—for EPI associated with chronic pancreatitis (CP) and cystic fibrosis (CF). Also, MS1819-SD is considered recombinant because it was created from new combinations of genetic material in yeast called yarrowia lipolytica. The drug id currently in phase II clinical developmental trial in patients with EPI. The study enrolled 24 participants, and it is estimated to be complete by December 2020.
Products detail in the report…
The treatment landscape of EPI majorly includes pancreatic enzyme replacement therapy (PERT), lifestyle modifications (e.g., avoidance of fatty foods, limitation of alcohol intake, cessation of smoking, and consumption of a well-balanced diet) and vitamin supplementation (primarily the fat-soluble vitamins A, D, E, and K). Pancreatic enzyme replacement therapy (PERT) is the first line therapeutic mainstay that is prescribed in patients. The pancreatic enzyme products (PEPs) used for PERT are extracts of porcine pancreas that contain all three pancreatic enzymes (i.e., amylase, protease, and lipase) in varying proportions. However, it is lipase that plays the paramount role in therapy. Pharmacological therapies are the mainstay treatment option followed by the patients with EPI. The market of EPI includes use of the drugs either as monotherapy and are not interchangeable. There are several approved drugs in the market of different classes.
The Exocrine Pancreatic Insufficiency (EPI) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Exocrine Pancreatic Insufficiency (EPI) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Exocrine Pancreatic Insufficiency (EPI) 7MM market is expected to change in the study period 2017–2030.
Key Findings
This section includes a glimpse of the Exocrine Pancreatic Insufficiency (EPI) 7MM market.
The United States Market Outlook
This section provides the total Exocrine Pancreatic Insufficiency (EPI) market size and market size by therapies in the United States.
EU-5 Market Outlook
The total Aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Exocrine Pancreatic Insufficiency (EPI) market size and market size by therapies in Japan are provided.
This section focusses on the rate of uptake of the potential drugs recently launched in the Exocrine Pancreatic Insufficiency market or expected to get launched in the market during the study period 2017-2030. The analysis covers Exocrine Pancreatic Insufficiency market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Exocrine Pancreatic Insufficiency key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Exocrine Pancreatic Insufficiency emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in Exocrine Pancreatic Insufficiency domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Exocrine Pancreatic Insufficiency market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Exocrine Pancreatic Insufficiency Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
1. Key Insights
2. Executive Summary
3. SWOT Analysis
4. Exocrine Pancreatic Insufficiency (EPI) Market Overview at a Glance
4.1. Market Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2017
4.2. Market Share (%) Distribution of Exocrine Pancreatic Insufficiency (EPI) in 2030
5. Disease Background and Overview: Exocrine Pancreatic Insufficiency (EPI)
5.1. Introduction
5.2. Biology and pathology of Exocrine Pancreatic Insufficiency
5.3. Pathophysiology of EPI
5.4. Causes and Risk Factors of EPI
5.4.1. EPI caused by pancreatic disorders
5.4.2. EPI caused by extrapancreatic disorders
5.5. Serum nutritional markers for prediction of pancreatic exocrine insufficiency in chronic pancreatitis
5.5.1. Disorders of Carbohydrate Metabolism
5.5.1. Disorders of Lipid Metabolism
5.6. Diagnosis
5.6.1. Fecal elastase-1 test (FE-1)
5.6.2. Serum trypsinogen
5.6.3. Fecal chymotrypsin
5.6.4. Breath tests
5.6.5. Coefficient of fat absorption (CFA)
5.6.6. Preoperative Evaluation
5.6.7. Direct pancreatic function test
5.6.8. Secretin-enhanced magnetic resonance cholangiopancreatography (MRCP)
5.6.9. Differential Diagnosis of exocrine pancreatic insufficiency
6. Recognized Establishments
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. 7 Major Markets
7.2.1. Prevalence of Causative Indications of EPI in the 7MM
7.2.2. Prevalence of Exocrine Pancreatic Insufficiency in the 7MM
8. Country-wise Epidemiology of Exocrine Pancreatic Insufficiency (EPI)
8.1. United States
8.1.1. Prevalence of Causative Indications of EPI in the United States
8.1.2. Prevalence of Exocrine Pancreatic Insufficiency in the United States
8.2. EU5 Countries
8.2.1. Assumption and Rationale
8.3. Germany
8.3.1. Prevalence of Causative Indications of EPI in Germany
8.3.2. Prevalence of Exocrine Pancreatic Insufficiency in Germany
8.4. France
8.4.1. Prevalence of Causative Indications of EPI in France
8.4.2. Prevalence of Exocrine Pancreatic Insufficiency in France
8.5. Italy
8.5.1. Prevalence of Causative Indications of EPI in Italy
8.5.2. Prevalence of Exocrine Pancreatic Insufficiency in Italy
8.6. Spain
8.6.1. Prevalence of Causative Indications of EPI in Spain
8.6.2. Prevalence of Exocrine Pancreatic Insufficiency in Spain
8.7. The United Kingdom
8.7.1. Prevalence of Causative Indications of EPI in the United Kingdom
8.7.2. Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom
8.8. Japan
8.8.1. Assumption and Rationale
8.8.2. Prevalence of Causative Indications of EPI in Japan
8.8.3. Prevalence of Exocrine Pancreatic Insufficiency in Japan
9. Treatment
9.1. Dietary management and lifestyle changes
9.2. Pancreatic enzyme replacement therapy (PERT)
9.3. Patient Journey of EPI with Gastrointestinal Disorders in Diabetes
10. Unmet Needs
11. Marketed Drugs
11.1. Key-cross Competition
11.2 Pertzye (pancrelipase): Digestive Care
11.2.1. Product Description
11.2.2. Regulatory Milestone
11.2.3. Other Developmental Activities
11.2.4. Safety and Efficacy
11.2.5. Product Profile
11.3. Creon (pancrelipase)/Lipacreon: AbbVie
11.3.1. Product Description
11.3.2. Regulatory Milestone
11.3.3. Other Developmental Activities
11.3.4. Safety and Efficacy
11.3.5. Pipeline Activity
11.3.6. Product Profile
11.4. Zenpep (pancrelipase): Nestle
11.4.1. Product Description
11.4.2. Regulatory Milestone
11.4.3. Other Developmental Activities
11.4.4. Safety and Efficacy
11.4.5. Product Profile
11.5 Pancreaze: Janssen Pharmaceuticals
11.5.1. Product Description
11.5.2. Regulatory Milestone
11.5.3. Other Developmental Activities
11.5.4. Safety and Efficacy
11.5.5. Product Profile
11.6 Viokace (pancrelipase): Aptalis Pharma/Forest Laboratories
11.6.1. Drug Description
11.6.2. Regulatory Milestones
11.6.3. Other Development Activities
11.6.4. Safety and Efficacy
11.6.5. Product Profile
11.7. RELiZORB: Alcresta Therapeutics
11.7.1. Product Description
11.7.2. Regulatory Milestone
11.7.3. Other Developmental Activities
11.7.4. Safety and efficacy
11.7.5. Product Profile
11.8 Ultresa (pancrelipase): Aptalis Pharma/Forest Laboratories
11.8.1. Drug Description
11.8.2. Regulatory Milestones
11.8.3. Other Development Activities
11.8.4. Safety and Efficacy
11.8.5. Product Profile
12. Emerging Drugs
12.1 Omeprazole: Chiesi Farmaceutici
12.1.1. Product Description
12.1.2. Clinical Development
12.1.3. Product Profile
12.2 MS1819-SD: AzurRx BioPharma
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Product Profile
13. Exocrine Pancreatic Insufficiency (EPI): 7 Major Market Analysis
13.1. Key Findings
13.2. Total Market Size of Exocrine Pancreatic Insufficiency (EPI) in the 7MM Countries
13.2.1. Market Size by Therapies
14. Conjoint Analysis
15. 7MM Market Outlook
16. United States Market Size
16.1. Total Market size of Exocrine Pancreatic Insufficiency (EPI)
16.2. Market Size by Therapies
17. EU-5 Market Size
17.1. Germany
17.1.1. Total Market size of Exocrine Pancreatic Insufficiency (EPI)
17.1.2. Market Size by Therapies
17.2. France
17.2.1. Total Market size of Exocrine Pancreatic Insufficiency (EPI)
17.2.2. Market Size of Exocrine Pancreatic Insufficiency (EPI) by Therapies
17.3. Italy
17.3.1. Total Market Size of Exocrine Pancreatic Insufficiency (EPI)
17.3.2. Market Size of Exocrine Pancreatic Insufficiency (EPI) by Therapies
17.4. Spain
17.4.1. Total Market Size of Exocrine Pancreatic Insufficiency (EPI)
17.4.2. Market Size of Exocrine Pancreatic Insufficiency (EPI) by Therapies
17.5. United Kingdom
17.5.1. Total Market Size of Exocrine Pancreatic Insufficiency (EPI)
17.5.2. Market Size by Therapies
17.6. Japan Market Size
17.6.1. Total Market Size of Exocrine Pancreatic Insufficiency (EPI)
17.6.2. Market Size by Therapies
18. Access and Reimbursement Overview: Exocrine Pancreatic Insuffficiency (EPI)
19. Case Reports
19.1. A Case Report of exocrine pancreatic insufficiency in palliative care patient
19.2. Case Report of a Patient with Pancreatic Exocrine Insufficiency and Enteral Feeding
19.3. Case Report of a Pancreatic Exocrine Insufficiency Patient with Systemic Edema after Pancreaticoduodenectomy
20. Market Drivers
21. Market Barriers
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
List of Tables:
Table 1: Summary of Exocrine Pancreatic Insufficiency (EPI) Epidemiology, and Key Events (2017–2030)
Table 2: Summary of Exocrine Pancreatic Insufficiency (EPI) Market, and Key Events (2017–2030)
Table 3: Common symptoms shared by EPI and other gastrointestinal conditions
Table 4: EPI caused by pancreatic disorders
Table 5: EPI caused by extrapancreatic disorders
Table 6: Pancreatic Function Tests—Indirect and Direct Tests
Table 7: Prevalence of Causative Indications of EPI in the 7MM (2017–2030)
Table 8: Prevalence of Exocrine Pancreatic Insufficiency in the 7MM (2017–2030)
Table 9: Prevalence of exocrine pancreatic insufficiency in individuals with predisposing conditions
Table 10: Prevalence of Causative Indications of EPI in the United States (2017–2030)
Table 11: Prevalence of Exocrine Pancreatic Insufficiency in the United States (2017–2030)
Table 12: EPI caused by pancreatic disorders
Table 13: Prevalence of Causative Indications of EPI in Germany (2017–2030)
Table 14: Prevalence of Exocrine Pancreatic Insufficiency in Germany (2017–2030)
Table 15: Prevalence of Causative Indications of EPI in France (2017–2030)
Table 16: Prevalence of Exocrine Pancreatic Insufficiency in France (2017–2030)
Table 17: Prevalence of Causative Indications of EPI in Italy (2017–2030)
Table 18: Prevalence of Exocrine Pancreatic Insufficiency in Italy (2017–2030)
Table 19: Prevalence of Causative Indications of EPI in Spain (2017–2030)
Table 20: Prevalence of Exocrine Pancreatic Insufficiency in Spain (2017–2030)
Table 21: Prevalence of Causative Indications of EPI in the United Kingdom (2017–2030)
Table 22: Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom (2017–2030)
Table 23: Prevalence of Causative Indications of EPI in Japan (2017–2030)
Table 24: Prevalence of Exocrine Pancreatic Insufficiency in Japan (2017–2030)
Table 25: Current Food and Drug Administration (FDA) approved pancreatic enzyme replacement therapies (PERTs)
Table 26: Comparison of Marketed Drugs
Table 27: Omeprazole, Clinical Trial Description, 2020
Table 28: MS1819-SD, Clinical Trial Description, 2020
Table 29: 7 Major Market Size of Exocrine Pancreatic Insufficiency (EPI) in USD Million (2017–2030)
Table 30: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in the 7MM, in USD Million (2017–2030)
Table 31: United States Market Size of Exocrine Pancreatic Insufficiency (EPI), USD Million (2017–2030)
Table 32: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in the US, in USD Million (2017–2030)
Table 33: Germany Market Size of Exocrine Pancreatic Insufficiency (EPI), USD Million (2017–2030)
Table 34: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in Germany, in USD Million (2017–2030)
Table 35: France Market Size of Exocrine Pancreatic Insufficiency (EPI), USD Million (2017–2030)
Table 36: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in France, in USD Million (2017–2030)
Table 37: Italy Market Size of Exocrine Pancreatic Insufficiency (EPI), USD Million (2017–2030)
Table 38: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in Italy, in USD Million (2017–2030)
Table 39: Spain Market Size of Exocrine Pancreatic Insufficiency (EPI), USD Million (2017–2030)
Table 40: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in Spain, in USD Million (2017–2030)
Table 41: United Kingdom Market Size of Exocrine Pancreatic Insufficiency (EPI), USD Million (2017–2030)
Table 42: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in the UK, in USD Million (2017–2030)
Table 43: Japan Market Size of Exocrine Pancreatic Insufficiency (EPI), USD Million (2017–2030)
Table 44: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in Japan,in USD Million (2017–2030)
List of Figures:
Figure 1: Exocrine Pancreatic Insufficiency SWOT Analysis
Figure 2: The pathology of exocrine pancreatic insufficiency
Figure 3: Relationship between extrapancreatic diseases/conditions and PEI
Figure 4: Basis of pancreatic function breath tests.
Figure 5: Prevalence of Causative Indications of EPI in the 7MM (2017–2030)
Figure 6: Prevalence of Exocrine Pancreatic Insufficiency in the 7MM (2017–2030)
Figure 7: Prevalence of Causative Indications of EPI in the United States (2017–2030)
Figure 8: Prevalence of Exocrine Pancreatic Insufficiency in the United States (2017–2030)
Figure 9: Prevalence of Causative Indications of EPI in Germany (2017–2030)
Figure 10: Prevalence of Exocrine Pancreatic Insufficiency in Germany (2017–2030)
Figure 11: Prevalence of Causative Indications of EPI in France (2017–2030)
Figure 12: Prevalence of Exocrine Pancreatic Insufficiency in France (2017–2030)
Figure 13: Prevalence of Causative Indications of EPI in Italy (2017–2030)
Figure 14: Prevalence of Exocrine Pancreatic Insufficiency in Italy (2017–2030)
Figure 15: Prevalence of Causative Indications of EPI in Spain (2017–2030)
Figure 16: Prevalence of Exocrine Pancreatic Insufficiency in Spain (2017–2030)
Figure 17: Prevalence of Causative Indications of EPI in the United Kingdom (2017–2030)
Figure 18: Prevalence of Exocrine Pancreatic Insufficiency in the United Kingdom (2017–2030)
Figure 19: Prevalence of Causative Indications of EPI in Japan (2017–2030)
Figure 20: Prevalence of Exocrine Pancreatic Insufficiency in Japan (2017–2030)
Figure 21: Fundamental aspect of the care of patients with EPI
Figure 22: Management of the pancreatic enzyme replacement therapy. PPI: proton pump inhibitors.
Figure 23: Assessment-of-gastrointestinal-disorders-in-patients-with-diabetes
Figure 24: 7 Major Market Size of Exocrine Pancreatic Insufficiency (EPI) in USD Million (2017–2030)
Figure 25: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in the 7MM, in USD Million (2017–2030)
Figure 26: Market Size of Exocrine Pancreatic Insufficiency (EPI) in the United States, USD Millions (2017–2030)
Figure 27: Market size of Exocrine Pancreatic Insufficiency (EPI) by therapies in the US, in USD Million (2017–2030)
Figure 28: Market Size of Exocrine Pancreatic Insufficiency (EPI) in Germany, USD Million (2017–2030)
Figure 29: Market Size of Exocrine Pancreatic Insufficiency (EPI) by therapies, in Germany, in USD Million (2017–2030)
Figure 30: Market Size of Exocrine Pancreatic Insufficiency (EPI) in France, USD Million (2017–2030)
Figure 31: Market Size of Exocrine Pancreatic Insufficiency (EPI) by therapies, in France, in USD Million (2017–2030)
Figure 32: Market Size of Exocrine Pancreatic Insufficiency (EPI) in Italy, USD Million (2017–2030)
Figure 33: Market Size of Exocrine Pancreatic Insufficiency (EPI) by therapies, in Italy, in USD Million (2017–2030)
Figure 34: Market Size of Exocrine Pancreatic Insufficiency (EPI) in Spain, USD Million (2017–2030)
Figure 35: Market Size of Exocrine Pancreatic Insufficiency (EPI) by therapies in Spain, in USD Million (2017–2030)
Figure 36: Market Size of Exocrine Pancreatic Insufficiency (EPI) in the UK, USD Million (2017–2030)
Figure 37: Market Size of Exocrine Pancreatic Insufficiency (EPI) by therapies in the UK, in USD Million (2017–2030)
Figure 38: Market Size of Exocrine Pancreatic Insufficiency (EPI) in Japan, USD Million (2017–2030)
Figure 39: Market Size of Exocrine Pancreatic Insufficiency (EPI) by therapies in Japan, in USD Million (2017–2030)
Digestive Care
AbbVie
Nestle
Janssen Pharmaceuticals
Aptalis Pharma/Forest Laboratories
Alcresta Therapeutics
Aptalis Pharma/Forest Laboratories
Chiesi Farmaceutici
AzurRx BioPharma
